Monthly
US$200
Billed every month
Sign in to subscribeAs of 13 November 2026, for Furosemide Injection, 6 applications are listed as under review at China's CDE; 3 companies have filed new generic applications in 2026; the chemical-drug catalogue lists 27 holders.
Companies, stages and changes, with each record available on this page.
Last 90 days: Marketing application approved: 1 applicationAccepted: 1 application
Current coverage may be incomplete
The brand names come from the US FDA Orange Book and describe US listing records for this active ingredient. They do not indicate that products under these brand names are approved or sold in China, or that Chinese applicants are affiliated with US holders.
Orange Book source export date: 2026/11/06. Version: 2026-11-06.
Showing 4 of 4 distinct brand names.
A brand with different source forms or statuses can appear on multiple rows and in both groups. Distinct brand names are counted once globally, with a limit of five.
Verified official English dosage form: Injection. Listings are grouped by the source dosage form and route; records without a clear correspondence are listed in the other group. Grouping does not establish product equivalence.
| Brand name | Applicant (source text) | Application number | Dosage form (source text) | Route (source text) | Marketing status (source text) | Approval date |
|---|---|---|---|---|---|---|
| LASIX | SANOFI AVENTIS US LLC | NDA 016363 · Product no. 001 | INJECTABLE | INJECTION | DISCONTINUED | Approved prior to 1982 (exact date not listed) |
| Brand name | Applicant (source text) | Application number | Dosage form (source text) | Route (source text) | Marketing status (source text) | Approval date |
|---|---|---|---|---|---|---|
| FUROSCIX | SCPHARMACEUTICALS INC A WHOLLY OWNED SUB OF MANNKIND CORP | NDA 209988 · Product no. 001 | SOLUTION | SUBCUTANEOUS | HUMAN PRESCRIPTION DRUG | 2022/10/07 |
| LASIX ONYU | SQ INNOVATION INC | NDA 217294 · Product no. 001 | SOLUTION | SUBCUTANEOUS | HUMAN PRESCRIPTION DRUG | 2025/10/07 |
| FUROSCIX READYFLOW (AUTOINJECTOR) | SCPHARMACEUTICALS INC A WHOLLY OWNED SUB OF MANNKIND CORP | NDA 209988 · Product no. 002 | SOLUTION | SUBCUTANEOUS | HUMAN PRESCRIPTION DRUG | 2026/07/23 |
| LASIX | VALIDUS PHARMACEUTICALS LLC | NDA 016273 · Product no. 001, 002, 003 | TABLET | ORAL | DISCONTINUED | Approved prior to 1982 (exact date not listed) |
| LASIX | SANOFI AVENTIS US LLC | NDA 017688 · Product no. 001 | SOLUTION | ORAL | DISCONTINUED | Approved prior to 1982 (exact date not listed) |
Same-form/route listings come first, followed by other forms/routes. Within each group, source prescription/OTC listings precede discontinued listings; unknown statuses are last. Each status bucket is ordered by earliest approval date, ascending: pre-1982 records first, missing dates last; ties by brand name, application number and product number. The first five distinct brands in this order are selected globally. All retained source facts for those brands are shown in their own groups; a brand spanning both groups counts once.
Each source is counted separately. Expand a list to inspect companies, identifiers, dates and sources.
Legal reference identifiers are retained verbatim. Company labels use official English entries where available, or a visibly marked fixed romanization. Unverified drug names retain the Chinese source name with a No verified English name marker. Other Chinese free text is not displayed; use the source links or source-name columns in CSV exports.
Loaded records: 27 holders; 14 in the quality-and-efficacy consistency-evaluation category, and 12 in the new chemical-registration-classification generic category. Category counts may overlap.
| Marketing authorization holder | Manufacturer | Approval number | Approved | Strength / specification | Catalogue category (source text) | View source |
|---|---|---|---|---|---|---|
| Shanghai Jin Di Jiu Zhou Pharma (An Yang) Co., Ltd. romanized | Shanghai Jin Di Jiu Zhou Pharma (An Yang) Co., Ltd. romanized | 国药准字H20045164 | 2026/03/09 | 2ml:20mg | Drug that passed quality-and-efficacy consistency evaluation | CDE |
| Jiangsu Run Heng Pharmaceutical Co., Ltd. romanized | Jiangsu Run Heng Pharmaceutical Co., Ltd. romanized | 国药准字H20263434 | 2026/02/25 | 2ml:20mg | Generic approved under the new chemical-drug registration classification | CDE |
| Jiu Quan Da De Li Pharmaceutical Co., Ltd. romanized | Jiu Quan Da De Li Pharmaceutical Co., Ltd. romanized | 国药准字H20263144 | 2026/01/20 | 2ml:20mg | Generic approved under the new chemical-drug registration classification | CDE |
| Yunnan Yao Ke Yuan Biopharmaceuticals Co., Ltd. romanized | Chu Xiong He Chuang Pharma Co., Ltd. romanized | 国药准字H20253555 | 2025/03/04 | 2ml:20mg | Generic approved under the new chemical-drug registration classification | CDE |
| Jilin Sheng Hui Nan Chang Long Sheng Hua Pharma Co., Ltd. romanized | Jilin Sheng Hui Nan Chang Long Sheng Hua Pharma Co., Ltd. romanized | 国药准字H20249770 | 2024/12/25 | 2ml:20mg | Not stated by source | CDE |
| Shijiazhuang No.4 Pharmaceutical Co., Ltd. | Shijiazhuang No.4 Pharmaceutical Co., Ltd. | 国药准字H13020021 | 2024/12/20 | 2ml:20mg | Drug that passed quality-and-efficacy consistency evaluation | CDE |
| Shi Yao Yin Hu Pharmaceutical Co., Ltd. romanized | Shi Yao Yin Hu Pharmaceutical Co., Ltd. romanized | 国药准字H14022627 | 2024/12/09 | 2ml:20mg | Drug that passed quality-and-efficacy consistency evaluation | CDE |
| CSPC OUYI PHARMACEUTICAL CO., LTD. | CSPC OUYI PHARMACEUTICAL CO., LTD. | 国药准字H13021034 | 2024/12/05 | 2ml:20mg | Drug that passed quality-and-efficacy consistency evaluation | CDE |
| Wuhan Jiu An Pharma Co., Ltd. romanized | Sichuan Mei Da Kang Jia Le Pharma Co., Ltd. romanized | 国药准字H20249587 | 2024/12/01 | 2ml:20mg | Generic approved under the new chemical-drug registration classification | CDE |
| Wuhan Jiu An Pharma Co., Ltd. romanized | Sichuan Mei Da Kang Jia Le Pharma Co., Ltd. romanized | 国药准字H20249586 | 2024/12/01 | 10ml:100mg | Generic approved under the new chemical-drug registration classification | CDE |
| Sui Cheng Pharma Co., Ltd. romanized | Sui Cheng Pharma Co., Ltd. romanized | 国药准字H41021056 | 2024/11/12 | 2ml:20mg | Drug that passed quality-and-efficacy consistency evaluation | CDE |
| Ren He Yi Kang Group Co., Ltd. romanized | Hebei Ren He Yi Kang Pharma Co., Ltd. romanized | 国药准字H20244406 | 2024/07/09 | 10ml:100mg | Generic approved under the new chemical-drug registration classification | CDE |
| Zhongguo Da Zhong Pharmaceutical Co., Ltd. romanized | Zhongguo Da Zhong Pharmaceutical Co., Ltd. romanized | 国药准字H20243838 | 2024/05/28 | 2ml:20mg | Generic approved under the new chemical-drug registration classification | CDE |
| Anhui Chang Jiang Pharma Co., Ltd. romanized | Anhui Chang Jiang Pharma Co., Ltd. romanized | 国药准字H34021984 | 2024/01/04 | 2ml:20mg | Drug that passed quality-and-efficacy consistency evaluation | CDE |
| Jilin Zhen Ao Pharmaceutical Co., Ltd. romanized | Jilin Zhen Ao Pharmaceutical Co., Ltd. romanized | 国药准字H20233896 | 2023/06/30 | 2ml:20mg | Generic approved under the new chemical-drug registration classification | CDE |
| Chengdu Brilliant Pharmaceutical Co., Ltd. | Hainan Brilliant Pharmaceutical Co., Ltd. | 国药准字H20237064 | 2023/06/14 | 10ml:100mg | Drug that passed quality-and-efficacy consistency evaluation | CDE |
| Chengdu Brilliant Pharmaceutical Co., Ltd. | Hainan Brilliant Pharmaceutical Co., Ltd. | 国药准字H32021527 | 2023/06/14 | 2ml:20mg | Drug that passed quality-and-efficacy consistency evaluation | CDE |
| Jia Shi (Hunan) Pharmaceuticals Technology Co., Ltd. romanized | Hunan Wu Zhou Tong Pharma Co., Ltd. romanized | 国药准字H20233276 | 2023/03/15 | 2ml:20mg | Generic approved under the new chemical-drug registration classification | CDE |
| Guangzhou Rui Er Pharmaceuticals Technology Co., Ltd. romanized | Chengdu Shi Hai Tong Pharma Co., Ltd. romanized | 国药准字H20233104 | 2023/01/31 | 2ml:20mg | Generic approved under the new chemical-drug registration classification | CDE |
| Hangzhou Minsheng Pharmaceutical Co., Ltd | Hangzhou Minsheng Pharmaceutical Co., Ltd | 国药准字H20233048 | 2023/01/10 | 2ml:20mg | Generic approved under the new chemical-drug registration classification | CDE |
| Shandong Bei Da Gao Ke Hua Tai Pharmaceutical Co., Ltd. romanized | Yang Zhou Zhong Bao Pharma Co., Ltd. romanized | 国药准字H20223898 | 2022/11/30 | 2ml:20mg | Generic approved under the new chemical-drug registration classification | CDE |
| Hubei Tian Sheng Pharma Co., Ltd. romanized | Hubei Tian Sheng Pharma Co., Ltd. romanized | 国药准字H42020417 | 2022/11/11 | 2ml:20mg | Drug that passed quality-and-efficacy consistency evaluation | CDE |
| Shanghai He Feng Pharmaceutical Co., Ltd. romanized | Shanghai He Feng Pharmaceutical Co., Ltd. romanized | 国药准字H31021063 | 2022/10/09 | 2ml:20mg | Drug that passed quality-and-efficacy consistency evaluation | CDE |
| SHANDONG XINHUA PHARMACEUTICAL COMPANY LIMITED | SHANDONG XINHUA PHARMACEUTICAL COMPANY LIMITED | 国药准字H37020293 | 2022/10/08 | 2ml:20mg | Drug that passed quality-and-efficacy consistency evaluation | CDE |
| Shanghai Zhao Hui Pharma Co., Ltd. romanized | Shanghai Zhao Hui Pharma Co., Ltd. romanized | 国药准字H31021075 | 2022/03/09 | 2ml:20mg | Drug that passed quality-and-efficacy consistency evaluation | CDE |
| Henan Run Hong Pharmaceutical Co., Ltd. romanized | Henan Run Hong Pharmaceutical Co., Ltd. romanized | 国药准字H41020310 | 2022/02/22 | 2ml:20mg | Drug that passed quality-and-efficacy consistency evaluation | CDE |
| Tianjin Jin Yao Pharma Co., Ltd. romanized | Tianjin Jin Yao Pharma Co., Ltd. romanized | 国药准字H12020527 | 2022/01/12 | 2ml:20mg | Drug that passed quality-and-efficacy consistency evaluation | CDE |
| Tianjin Jin Yao Group Hubei Tian Yao Pharma Co., Ltd. romanized | Tianjin Jin Yao Group Hubei Tian Yao Pharma Co., Ltd. romanized | 国药准字H42020034 | 2021/12/21 | 2ml:20mg | Drug that passed quality-and-efficacy consistency evaluation | CDE |
| Nanjing Ze Heng Pharmaceuticals Technology Kai Fa Co., Ltd. romanized | Ya Bang Pharmaceuticals Co., Ltd. romanized | 国药准字H20213920 | 2021/12/08 | 2ml:20mg | Generic approved under the new chemical-drug registration classification | CDE |
| Ren He Yi Kang Group Co., Ltd. romanized | Hebei Ren He Yi Kang Pharma Co., Ltd. romanized | 国药准字H20244405 | 2024/07/09 | 2ml:20mg | Generic approved under the new chemical-drug registration classification | CDE |
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
Loaded records: 57 distinct approval numbers and 55 companies.
| Company / applicant | Approval number | Strength / specification | NHSA class | NHSA drug code | View source |
|---|---|---|---|---|---|
| Guangdong Nan Guo Pharma Co., Ltd. romanized | 国药准字H44022506 | 2ml:20mg | Category A | XC03CAF056B002010100315 | NHSA |
| Guangdong Xin Feng Pharma Co., Ltd. romanized | 国药准字H44022003 | 2ml:20mg | Category A | XC03CAF056B002010100326 | NHSA |
| Shanghai Zhao Hui Pharma Co., Ltd. romanized | 国药准字H31021075 | 2ml:20mg | Category A | XC03CAF056B002010100665 | NHSA |
| Shanghai He Feng Pharmaceutical Co., Ltd. romanized | 国药准字H31021063 | 2ml:20mg | Category A | XC03CAF056B002010100673 | NHSA |
| Beijing Jing Feng Pharmaceutical Group Co., Ltd. romanized | 国药准字H12020527 | 2ml:20mg | Category A | XC03CAF056B002010100874 | NHSA |
| Zhongguo Da Zhong Pharmaceutical Co., Ltd. romanized | 国药准字H20243838 | 2ml:20mg | Category A | XC03CAF056B002010100967 | NHSA |
| Xi Nan Pharma Co., Ltd. romanized | 国药准字H50020101 | 2ml:20mg | Category A | XC03CAF056B002010100978 | NHSA |
| Jiangsu Yue Xing Pharma Co., Ltd. romanized | 国药准字H32020064 | 2ml:20mg | Category A | XC03CAF056B002010101631 | NHSA |
| Hainan Brilliant Pharmaceutical Co., Ltd. | 国药准字H32021527 | 2ml:20mg | Category A | XC03CAF056B002010101708 | NHSA |
| Jiangsu Lang Ou Pharma Co., Ltd. romanized | 国药准字H32021067 | 2ml:20mg | Category A | XC03CAF056B002010101723 | NHSA |
| Wuhan Fu Xing Bio Pharma Co., Ltd. romanized | 国药准字H42023005 | 2ml:20mg | Category A | XC03CAF056B002010101799 | NHSA |
| Hubei Tian Sheng Pharma Co., Ltd. romanized | 国药准字H42020417 | 2ml:20mg | Category A | XC03CAF056B002010101842 | NHSA |
| Hubei Jin Yao Pharma Co., Ltd. romanized | 国药准字H42020034 | 2ml:20mg | Category A | XC03CAF056B002010101866 | NHSA |
| Wuhan Jiu An Pharma Co., Ltd. romanized | 国药准字H20249587 | 2ml:20mg | Category A | XC03CAF056B002010101949 | NHSA |
| Yi Chang Ren Fu Pharma Co., Ltd. romanized | 国药准字H42022075 | 2ml:20mg | Category A | XC03CAF056B002010102000 | NHSA |
| Chengdu Brilliant Pharmaceutical Co., Ltd. | 国药准字H20237064 | 10ml:100mg | Category A | XC03CAF056B002010102013 | NHSA |
| Chengdu Di Yi Pharmaceutical Co., Ltd. romanized | 国药准字H51023139 | 2ml:20mg | Category A | XC03CAF056B002010102065 | NHSA |
| Sichuan Mei Da Kang Hua Kang Pharma Co., Ltd. romanized | 国药准字H51023158 | 2ml:20mg | Category A | XC03CAF056B002010102087 | NHSA |
| Xian Feng Hua Pharma Co., Ltd. romanized | 国药准字H61021124 | 2ml:20mg | Category A | XC03CAF056B002010102420 | NHSA |
| Xian Di Sai Bio Pharma Co., Ltd. romanized | 国药准字H61021139 | 2ml:20mg | Category A | XC03CAF056B002010102470 | NHSA |
| Hebei Wu Luo Pharma Co., Ltd. romanized | 国药准字H13021427 | 2ml:20mg | Category A | XC03CAF056B002010102601 | NHSA |
| Shijiazhuang No.4 Pharmaceutical Co., Ltd. | 国药准字H13020021 | 2ml:20mg | Category A | XC03CAF056B002010102677 | NHSA |
| CSPC OUYI PHARMACEUTICAL CO., LTD. | 国药准字H13021034 | 2ml:20mg | Category A | XC03CAF056B002010102770 | NHSA |
| Shanxi Guo Run Pharmaceutical Co., Ltd. romanized | 国药准字H14020650 | 2ml:20mg | Category A | XC03CAF056B002010102839 | NHSA |
| Shi Yao Yin Hu Pharmaceutical Co., Ltd. romanized | 国药准字H14022627 | 2ml:20mg | Category A | XC03CAF056B002010102954 | NHSA |
| Ya Bao Pharma Group Co., Ltd. romanized | 国药准字H20055861 | 2ml:20mg | Category A | XC03CAF056B002010102987 | NHSA |
| Shanghai Jin Di Jiu Zhou Pharma (An Yang) Co., Ltd. romanized | 国药准字H20045164 | 2ml:20mg | Category A | XC03CAF056B002010102994 | NHSA |
| Kai Feng Pharmaceutical (Group) Co., Ltd. romanized | 国药准字H41021794 | 2ml:20mg | Category A | XC03CAF056B002010103139 | NHSA |
| Henan Run Hong Pharmaceutical Co., Ltd. romanized | 国药准字H41020310 | 2ml:20mg | Category A | XC03CAF056B002010103257 | NHSA |
| Chang Bai Shan Pharmaceutical Co., Ltd. romanized | 国药准字H22024699 | 2ml:20mg | Category A | XC03CAF056B002010103291 | NHSA |
| Zhong Jia Bio Technology (Hubei Sheng) Co., Ltd. romanized | 国药准字H20053949 | 2ml:20mg | Category A | XC03CAF056B002010103377 | NHSA |
| Jilin Sheng Hui Nan Chang Long Sheng Hua Pharma Co., Ltd. romanized | 国药准字H20249770 | 2ml:20mg | Category A | XC03CAF056B002010103421 | NHSA |
| Heilongjiang Sheng Ge Run Pharma Co., Ltd. romanized | 国药准字H23022350 | 2ml:20mg | Category A | XC03CAF056B002010103820 | NHSA |
| Shandong Fang Ming Pharma Group Co., Ltd. romanized | 国药准字H37021056 | 2ml:20mg | Category A | XC03CAF056B002010104083 | NHSA |
| SHANDONG XINHUA PHARMACEUTICAL COMPANY LIMITED | 国药准字H37020293 | 2ml:20mg | Category A | XC03CAF056B002010104187 | NHSA |
| Shandong Yi Jian Pharma Co., Ltd. romanized | 国药准字H20058876 | 2ml:20mg | Category A | XC03CAF056B002010104192 | NHSA |
| Shandong Sheng Lu Pharmaceutical Co., Ltd. romanized | 国药准字H37021208 | 2ml:20mg | Category A | XC03CAF056B002010104207 | NHSA |
| Xu Chang Wei Lai Pharmaceutical Co., Ltd. romanized | 国药准字H34020774 | 2ml:20mg | Category A | XC03CAF056B002010104338 | NHSA |
| Anhui Chang Jiang Pharma Co., Ltd. romanized | 国药准字H34021984 | 2ml:20mg | Category A | XC03CAF056B002010104451 | NHSA |
| Hangzhou Minsheng Pharmaceutical Co., Ltd | 国药准字H20233048 | 2ml:20mg | Category A | XC03CAF056B002010104494 | NHSA |
| Fujian Nan Shao Lin Pharma Co., Ltd. romanized | 国药准字H35020028 | 2ml:20mg | Category A | XC03CAF056B002010104784 | NHSA |
| Yunnan Bai Yao Group Co., Ltd. romanized | 国药准字H53020033 | 2ml:20mg | Category A | XC03CAF056B002010105607 | NHSA |
| Gansu Lan Yao Pharma Co., Ltd. romanized | 国药准字H62020717 | 2ml:20mg | Category A | XC03CAF056B002010105863 | NHSA |
| Jiu Quan Da De Li Pharmaceutical Co., Ltd. romanized | 国药准字H20263144 | 2ml:20mg | Category A | XC03CAF056B002010105888 | NHSA |
| Jilin Zhen Ao Pharmaceutical Co., Ltd. romanized | 国药准字H20233896 | 2ml:20mg | Category A | XC03CAF056B002010109876 | NHSA |
| Hai Hong Heng Long (Hainan) Bio Technology Co., Ltd. romanized | 国药准字H20213920 | 2ml:20mg | Category A | XC03CAF056B002010110144 | NHSA |
| Xizang Zhu Feng Shou Gao Bio Pharma Co., Ltd. romanized | 国药准字H20223898 | 2ml:20mg | Category A | XC03CAF056B002010181161 | NHSA |
| Ren He Yi Kang Group Co., Ltd. romanized | 国药准字H20244405 | 2ml:20mg | Category A | XC03CAF056B002010183033 | NHSA |
| Hainan Jin Rui Bao Pharmaceuticals Technology Co., Ltd. romanized | 国药准字H20233276 | 2ml:20mg | Category A | XC03CAF056B002010183048 | NHSA |
| Guangzhou Rui Er Pharmaceuticals Technology Co., Ltd. romanized | 国药准字H20233104 | 2ml:20mg | Category A | XC03CAF056B002010183450 | NHSA |
| Yunnan Yao Ke Yuan Biopharmaceuticals Co., Ltd. romanized | 国药准字H20253555 | 2ml:20mg | Category A | XC03CAF056B002010184547 | NHSA |
| Jiangsu Run Heng Pharmaceutical Co., Ltd. romanized | 国药准字H20263434 | 2ml:20mg | Category A | XC03CAF056B002010185467 | NHSA |
| Guangdong Nan Guo Pharma Co., Ltd. romanized | 国药准字H44022506 | 2ml:20mg | Category A | XC03CAF056B002010200315 | NHSA |
| Guangdong Xin Feng Pharma Co., Ltd. romanized | 国药准字H44022003 | 2ml:20mg | Category A | XC03CAF056B002010200326 | NHSA |
| Shanghai He Feng Pharmaceutical Co., Ltd. romanized | 国药准字H31021063 | 2ml:20mg | Category A | XC03CAF056B002010200673 | NHSA |
| Xi Nan Pharma Co., Ltd. romanized | 国药准字H50020101 | 2ml:20mg | Category A | XC03CAF056B002010200978 | NHSA |
| Hainan Brilliant Pharmaceutical Co., Ltd. | 国药准字H32021527 | 2ml:20mg | Category A | XC03CAF056B002010201708 | NHSA |
| Jiangsu Lang Ou Pharma Co., Ltd. romanized | 国药准字H32021067 | 2ml:20mg | Category A | XC03CAF056B002010201723 | NHSA |
| Wuhan Fu Xing Bio Pharma Co., Ltd. romanized | 国药准字H42023005 | 2ml:20mg | Category A | XC03CAF056B002010201799 | NHSA |
| Hubei Jin Yao Pharma Co., Ltd. romanized | 国药准字H42020034 | 2ml:20mg | Category A | XC03CAF056B002010201866 | NHSA |
| Wuhan Jiu An Pharma Co., Ltd. romanized | 国药准字H20249587 | 2ml:20mg | Category A | XC03CAF056B002010201949 | NHSA |
| Chengdu Brilliant Pharmaceutical Co., Ltd. | 国药准字H20237064 | 10ml:100mg | Category A | XC03CAF056B002010202013 | NHSA |
| Sichuan Mei Da Kang Hua Kang Pharma Co., Ltd. romanized | 国药准字H51023158 | 2ml:20mg | Category A | XC03CAF056B002010202087 | NHSA |
| Xian Feng Hua Pharma Co., Ltd. romanized | 国药准字H61021124 | 2ml:20mg | Category A | XC03CAF056B002010202420 | NHSA |
| Shaanxi Dun Si Pharmaceutical Co., Ltd. romanized | 国药准字H61021680 | 2ml:20mg | Category A | XC03CAF056B002010202503 | NHSA |
| Hebei Wu Luo Pharma Co., Ltd. romanized | 国药准字H13021427 | 2ml:20mg | Category A | XC03CAF056B002010202601 | NHSA |
| Shijiazhuang No.4 Pharmaceutical Co., Ltd. | 国药准字H13020021 | 2ml:20mg | Category A | XC03CAF056B002010202677 | NHSA |
| CSPC OUYI PHARMACEUTICAL CO., LTD. | 国药准字H13021034 | 2ml:20mg | Category A | XC03CAF056B002010202770 | NHSA |
| Shi Yao Yin Hu Pharmaceutical Co., Ltd. romanized | 国药准字H14022627 | 2ml:20mg | Category A | XC03CAF056B002010202954 | NHSA |
| Shanghai Jin Di Jiu Zhou Pharma (An Yang) Co., Ltd. romanized | 国药准字H20045164 | 2ml:20mg | Category A | XC03CAF056B002010202994 | NHSA |
| Kai Feng Pharmaceutical (Group) Co., Ltd. romanized | 国药准字H41021794 | 2ml:20mg | Category A | XC03CAF056B002010203139 | NHSA |
| Henan Run Hong Pharmaceutical Co., Ltd. romanized | 国药准字H41020310 | 2ml:20mg | Category A | XC03CAF056B002010203257 | NHSA |
| Zhong Jia Bio Technology (Hubei Sheng) Co., Ltd. romanized | 国药准字H20053949 | 2ml:20mg | Category A | XC03CAF056B002010203377 | NHSA |
| Jilin Sheng Hui Nan Chang Long Sheng Hua Pharma Co., Ltd. romanized | 国药准字H20249770 | 2ml:20mg | Category A | XC03CAF056B002010203421 | NHSA |
| Shandong Fang Ming Pharma Group Co., Ltd. romanized | 国药准字H37021056 | 2ml:20mg | Category A | XC03CAF056B002010204083 | NHSA |
| SHANDONG XINHUA PHARMACEUTICAL COMPANY LIMITED | 国药准字H37020293 | 2ml:20mg | Category A | XC03CAF056B002010204187 | NHSA |
| Shandong Yi Jian Pharma Co., Ltd. romanized | 国药准字H20058876 | 2ml:20mg | Category A | XC03CAF056B002010204192 | NHSA |
| Xu Chang Wei Lai Pharmaceutical Co., Ltd. romanized | 国药准字H34020774 | 2ml:20mg | Category A | XC03CAF056B002010204338 | NHSA |
| Hangzhou Minsheng Pharmaceutical Co., Ltd | 国药准字H20233048 | 2ml:20mg | Category A | XC03CAF056B002010204494 | NHSA |
| Fujian Nan Shao Lin Pharma Co., Ltd. romanized | 国药准字H35020028 | 2ml:20mg | Category A | XC03CAF056B002010204784 | NHSA |
| Gansu Lan Yao Pharma Co., Ltd. romanized | 国药准字H62020717 | 2ml:20mg | Category A | XC03CAF056B002010205863 | NHSA |
| Jilin Zhen Ao Pharmaceutical Co., Ltd. romanized | 国药准字H20233896 | 2ml:20mg | Category A | XC03CAF056B002010209876 | NHSA |
| Xizang Zhu Feng Shou Gao Bio Pharma Co., Ltd. romanized | 国药准字H20223898 | 2ml:20mg | Category A | XC03CAF056B002010281161 | NHSA |
| Ren He Yi Kang Group Co., Ltd. romanized | 国药准字H20244405 | 2ml:20mg | Category A | XC03CAF056B002010283033 | NHSA |
| Guangzhou Rui Er Pharmaceuticals Technology Co., Ltd. romanized | 国药准字H20233104 | 2ml:20mg | Category A | XC03CAF056B002010283450 | NHSA |
| Yunnan Yao Ke Yuan Biopharmaceuticals Co., Ltd. romanized | 国药准字H20253555 | 2ml:20mg | Category A | XC03CAF056B002010284547 | NHSA |
| Jiangsu Run Heng Pharmaceutical Co., Ltd. romanized | 国药准字H20263434 | 2ml:20mg | Category A | XC03CAF056B002010285467 | NHSA |
| Shaanxi Dun Si Pharmaceutical Co., Ltd. romanized | 国药准字H61021680 | 2ml:20mg | Category A | XC03CAF056B002010302503 | NHSA |
| Sui Cheng Pharma Co., Ltd. romanized | 国药准字H41021056 | 2ml:20mg | Category A | XC03CAF056B002010303204 | NHSA |
| Jilin Sheng Hui Nan Chang Long Sheng Hua Pharma Co., Ltd. romanized | 国药准字H20249770 | 2ml:20mg | Category A | XC03CAF056B002010303421 | NHSA |
| Fujian Nan Shao Lin Pharma Co., Ltd. romanized | 国药准字H35020028 | 2ml:20mg | Category A | XC03CAF056B002010304784 | NHSA |
| Jilin Zhen Ao Pharmaceutical Co., Ltd. romanized | 国药准字H20233896 | 2ml:20mg | Category A | XC03CAF056B002010309876 | NHSA |
| Ren He Yi Kang Group Co., Ltd. romanized | 国药准字H20244405 | 2ml:20mg | Category A | XC03CAF056B002010383033 | NHSA |
| Sui Cheng Pharma Co., Ltd. romanized | 国药准字H41021056 | 2ml:20mg | Category A | XC03CAF056B002010403204 | NHSA |
| Shaanxi Dun Si Pharmaceutical Co., Ltd. romanized | 国药准字H61021680 | 2ml:20mg | Category A | XC03CAF056B002010502503 | NHSA |
| Shaanxi Dun Si Pharmaceutical Co., Ltd. romanized | 国药准字H61021680 | 2ml:20mg | Category A | XC03CAF056B002010602503 | NHSA |
| Shanghai Zhao Hui Pharma Co., Ltd. romanized | 国药准字H31021075 | 2ml:20mg | Category A | XC03CAF056B002020100665 | NHSA |
| Beijing Jing Feng Pharmaceutical Group Co., Ltd. romanized | 国药准字H12020527 | 2ml:20mg | Category A | XC03CAF056B002020100874 | NHSA |
| Hubei Tian Sheng Pharma Co., Ltd. romanized | 国药准字H42020417 | 2ml:20mg | Category A | XC03CAF056B002020101842 | NHSA |
| Wuhan Jiu An Pharma Co., Ltd. romanized | 国药准字H20249586 | 10ml:100mg | Category A | XC03CAF056B002020101949 | NHSA |
| Shanxi Guo Run Pharmaceutical Co., Ltd. romanized | 国药准字H14020650 | 2ml:20mg | Category A | XC03CAF056B002020102839 | NHSA |
| Jilin Sheng Ji An Yi Sheng Pharma Co., Ltd. romanized | 国药准字H22021500 | 2ml:20mg | Category A | XC03CAF056B002020103425 | NHSA |
| Shandong Sheng Lu Pharmaceutical Co., Ltd. romanized | 国药准字H37021208 | 2ml:20mg | Category A | XC03CAF056B002020104207 | NHSA |
| Anhui Chang Jiang Pharma Co., Ltd. romanized | 国药准字H34021984 | 2ml:20mg | Category A | XC03CAF056B002020104451 | NHSA |
| Hai Hong Heng Long (Hainan) Bio Technology Co., Ltd. romanized | 国药准字H20213920 | 2ml:20mg | Category A | XC03CAF056B002020110144 | NHSA |
| Ren He Yi Kang Group Co., Ltd. romanized | 国药准字H20244406 | 10ml:100mg | Category A | XC03CAF056B002020183033 | NHSA |
| Wuhan Jiu An Pharma Co., Ltd. romanized | 国药准字H20249586 | 10ml:100mg | Category A | XC03CAF056B002020201949 | NHSA |
| Ren He Yi Kang Group Co., Ltd. romanized | 国药准字H20244406 | 10ml:100mg | Category A | XC03CAF056B002020283033 | NHSA |
| Ren He Yi Kang Group Co., Ltd. romanized | 国药准字H20244406 | 10ml:100mg | Category A | XC03CAF056B002020383033 | NHSA |
| Hainan Jin Rui Bao Pharmaceuticals Technology Co., Ltd. romanized | 国药准字H20233276 | 2ml:20mg | Category A | XC03CAF056B002010283048 | NHSA |
Approval numbers and companies are deduplicated separately; packaging records remain individually listed. An empty insurance class means it is unstated. NHSA codes supply no approval date and do not establish the outcome of an acceptance number.
Loaded records: 6 filings and 6 distinct first applicants.
Generic 5 · Supplement 1
| Company / applicant | Acceptance number | Application type | Accepted | Strength / specification | View source |
|---|---|---|---|---|---|
| Anhui Shuang He Pharma Co., Ltd. romanized | CYHS2602123 | Generic | 2026/08/26 | Not stated by source | CDE |
| Jiangxi Tai Ji Li Biopharmaceutical Co., Ltd. romanized | CYHS2601301 | Generic | 2026/06/04 | Not stated by source | CDE |
| Xin He Yuan Sheng Pharmaceutical Co., Ltd. romanized | CYHS2600651 | Generic | 2026/03/12 | Not stated by source | CDE |
| Shandong Yi Jian Pharma Co., Ltd. romanized | CYHB2550377 | Supplement | 2025/12/02 | Not stated by source | CDE |
| Ya Bang Pharmaceuticals Co., Ltd. romanized | CYHS2503622 | Generic | 2025/10/11 | Not stated by source | CDE |
| Henan Pu Rui Pharma Co., Ltd. romanized | CYHS2503598 | Generic | 2025/10/09 | Not stated by source | CDE |
Loaded records: 3 filings and 3 distinct first applicants.
| Company / applicant | Acceptance number | Application type | Accepted | Strength / specification | View source |
|---|---|---|---|---|---|
| Anhui Shuang He Pharma Co., Ltd. romanized | CYHS2602123 | Generic | 2026/08/26 | Not stated by source | CDE |
| Jiangxi Tai Ji Li Biopharmaceutical Co., Ltd. romanized | CYHS2601301 | Generic | 2026/06/04 | Not stated by source | CDE |
| Xin He Yuan Sheng Pharmaceutical Co., Ltd. romanized | CYHS2600651 | Generic | 2026/03/12 | Not stated by source | CDE |
Non-component matches: 20 companies with A status and 0 I-status records. Component matches are listed separately and excluded from these counts.
| Name | Company / applicant | Registration number | Status | Name match | Source update date | View source |
|---|---|---|---|---|---|---|
| 呋塞米 · No verified English name | Huang Shi Fu Er Tai Pharmaceuticals Technology Co., Ltd. romanized | Y20250000155 | A | Exact ingredient | 2026/07/14 | CDE |
| 呋塞米 · No verified English name | Yun Peng Pharmaceuticals Group Co., Ltd. romanized | Y20250000026 | A | Exact ingredient | 2026/06/11 | CDE |
| 呋塞米 · No verified English name | Hainan Zhuo Ke Pharmaceutical Co., Ltd. romanized | Y20240001396 | A | Exact ingredient | 2026/06/11 | CDE |
| 呋塞米 · No verified English name | Hebei Guo Long Pharmaceutical Co., Ltd. romanized | Y20240001516 | A | Exact ingredient | 2026/07/21 | CDE |
| 呋塞米 · No verified English name | SRI KRISHNA PHARMACEUTICALS LIMITED UNIT IV | Y20230001118 | A | Exact ingredient | 2026/07/21 | CDE |
| 呋塞米 · No verified English name | Sichuan Sheng Yu Xin Pharma Co., Ltd. romanized | Y20240000125 | A | Exact ingredient | 2025/07/28 | CDE |
| 呋塞米 · No verified English name | Beijing Jing Feng Pharmaceutical (Shandong) Co., Ltd. romanized | Y20230000311 | A | Exact ingredient | 2026/10/21 | CDE |
| 呋塞米 · No verified English name | Sui Cheng Pharma Co., Ltd. romanized | Y20230000252 | A | Exact ingredient | 2024/06/12 | CDE |
| 呋塞米 · No verified English name | Hunan Ou Ya Pharma Co., Ltd. romanized | Y20220000566 | A | Exact ingredient | 2026/04/08 | CDE |
| 呋塞米 · No verified English name | Henan Jing Kang Pharmaceutical Co., Ltd. romanized | Y20220000320 | A | Exact ingredient | 2024/09/20 | CDE |
| 呋塞米 · No verified English name | Mangalam Drugs and Organics Ltd. | Y20200000835 | A | Exact ingredient | 2026/10/15 | CDE |
| 呋塞米 · No verified English name | Assia Chemical Industries Ltd. | Y20200001166 | A | Exact ingredient | 2025/05/17 | CDE |
| 呋塞米 · No verified English name | Guangzhou Bai Yun Shan Pharmaceuticals Group Co., Ltd. Bai Yun Shan Pharmaceutical Factory romanized | Y20219990005 | A | Exact ingredient | — | CDE |
| 呋塞米 · No verified English name | Curia India Private Limited | Y20190009097 | A | Exact ingredient | 2025/06/03 | CDE |
| 呋塞米 · No verified English name | Changzhou Ya Bang Pharmaceutical Co., Ltd. romanized | Y20190008722 | A | Exact ingredient | 2025/07/24 | CDE |
| 呋塞米 · No verified English name | Beijing Tai Yang Pharma Co., Ltd. romanized | Y20190005487 | A | Exact ingredient | — | CDE |
| 呋塞米 · No verified English name | Dong Bei Pharmaceutical Group Co., Ltd. romanized | Y20190003799 | A | Exact ingredient | 2024/04/24 | CDE |
| 呋塞米 · No verified English name | Tai Shan Shi Xin Ning Pharmaceutical Co., Ltd. romanized | Y20190002797 | A | Exact ingredient | 2026/02/27 | CDE |
| 呋塞米 · No verified English name | Beijing Jing Feng Pharmaceutical (Shandong) Co., Ltd. romanized | Y20190002195 | A | Exact ingredient | 2023/04/23 | CDE |
| 呋塞米 · No verified English name | Liao Yuan Shi Bai Kang Pharma Co., Ltd. romanized | Y20190002139 | A | Exact ingredient | 2026/03/04 | CDE |
| 呋塞米 · No verified English name | Ipca Laboratories Limited | Y20170000088 | A | Exact ingredient | 2024/06/27 | CDE |
A/I are source statuses. Matching uses exact ingredients, salt-normalized names and maintained combination components, without fuzzy matching. A-status companies are deduplicated by the first registered company. Components are excluded from headline counts; the register does not identify the associated formulation.
Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately.
Trial registration does not mean an application will follow.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
NHSA edition maintained to 2026-10-23; latest successful catalogue check: 2026/11/13 06:39. NHSA records lack approval dates; only an earlier edition or observation establishes precedence.
This source was last successfully updated at 2026/11/12 18:32; current coverage may be incomplete.
CYHS2501124 · 国药准字H20266489
Fact date: 2026/11/03 · Publication date: 2026/11/05 · Site observation date: 2026/11/06
The loaded NHSA codes and chemical-drug catalogue contain no evidence confirming an earlier same-name approval for this company. This does not establish the absence of an earlier approval.
View source · Table row 41 ↗CYHS2602123
Fact date: 2026/08/26 · Site observation date: 2026/10/22
View source ↗Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
The fully loaded edition was maintained to 2026-10-23. Publication lags maintenance: the verified 2026-10-16 edition was published on 10-28, a 12-day gap. This is not a fixed lag for every edition.
First index-page publication dates: 2026-10-29 to 2026-11-13; 2 pages pending. Covers loaded notices only, not a complete historical approval database.
Daily collection reads new registrations. Backfill covers registration numbers from 2025 onward (CTR2025/CTR2026), not first-publication years. States are dated observations; revisions are not tracked.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
Public-product searches scanned: 7/30; discovered pending details: 13. Record counts in unscanned portions remain unknown.
Filings are counted by acceptance number and filing companies by first applicant. Strengths may have separate applications. Drug names are normalized only for width and whitespace; distinct generic names, dosage forms and combinations remain separate. Unstated strengths are marked. Company counts from different sources must not be added together.
Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.
Free follow
Up to 3 drugs per email address, in one weekly digest. Starts after email confirmation; unsubscribe at any time.
Subscriptions
US$200
Billed every month
Sign in to subscribeUS$540
Billed every three months
US$180 per month
Sign in to subscribeUS$1,920
Billed every year
US$160 per month
Sign in to subscribeSeparate one-time purchase
Full table and CSV export for 12 months from payment, with monthly data updates. No automatic renewal.
Subscriptions and comparison-table access are purchased separately. Neither includes the other.
Billed by Creem, our merchant of record · Terms · Refund policy